在文旅消费赛道，复星多个产品线取得新年开门红，有望拉动今年板块业绩的增长。其中，上海豫园商 城新春假期累计接待客流近120万人次，同比提升超20%；Club Med国内五家精致"一价全包"度假村春 节核心假期六日平均入住率达90%；三亚.亚特兰蒂斯春节假期九日总营业额突破1.24亿元，同比增长 20%，创下历史最佳表现。 此外，在保险赛道，复星国内两家保险公司相继公布2025年保费和净利润录得可观增长。其中，复星联 合健康保险业务收入达78.4亿元，同比增长50%，增速在专业健康险公司中位居前列，全年实现净利润 1.3亿元，连续五年盈利；复星保德信人寿全年保险业务收入达125.98亿元，较上年增长36.17%，延续 了近年来的跨越式增长态势，实现净利润6.47亿元，同比大幅增长超450%，盈利规模与质量迈上全新 台阶。 3月2日，复星国际(00656.HK)发布回购公告，计划于2025年度业绩公告发布后至2026年股东周年大会 日，于公开市场回购股份，回购总金额不超过10亿港元。公告指出，"本公司认为，当前公司股价水准 未能充分反映公司长期价值，基于对公司长期发展前景的判断以及对股东利益的审慎考量，本公司将于 ...

市场分析人士认为，此次回购计划彰显了复星对未来发展的信心，尤其是近年来创新成果不断商业化落 地及全球化运营的深入推进，给予了复星在核心主业上实现持续增长的底气。 分析人士注意到，2026年开年以来，复星生物医药、文旅消费、保险等主业板块延续强劲势头。 在创新药赛道，研发突破与全球市场拓展齐头并进。例如，旗下生物创新药平台复宏汉霖与卫材株式会 社就H药汉斯状达成协议，布局日本这一全球第四大医药市场，潜在总金额超3亿美元。而在2025年， 复星的创新药商业化更是打开了巨大的全球市场空间，与辉瑞签订的全球独家许可协议潜在总金额超20 亿美元，与生物技术公司Clavis Bio达成的战略合作，可获得至多72.5亿美元付款。 在文旅消费赛道，复星多个产品线取得新年开门红，有望拉动今年板块业绩的增长。其中，上海豫园商 城新春假期累计接待客流近120万人次，同比提升超20%；Club Med国内五家精致"一价全包"度假村春 节核心假期六日平均入住率达90%；三亚·亚特兰蒂斯春节假期九日总营业额突破1.24亿元，同比增长 20%，创下历史最佳表现。 3月2日，复星国际（00656.HK）发布回购公告，计划于2025年度业绩公 ...

根据公开信息，此前复星国际于2月27日斥资4823.54万港元回购1302.7万股。公告显示，自2022年1月1 日起至本次公告，复星国际已累计回购2.58859亿股，约占已发行股份总数的3.17%，总金额约11.9亿港 元。 本次公告同时强调，"在现行估值水准下实施回购符合本公司及股东整体利益。" 在创新药赛道，研发突破与全球市场拓展齐头并进。例如，旗下生物创新药平台复宏汉霖与卫材株式会 社就H药汉斯状达成协议，布局日本这一全球第四大医药市场，潜在总金额超3亿美元。而在2025年， 复星的创新药商业化更是打开了巨大的全球市场空间，与辉瑞签订的全球独家许可协议潜在总金额超20 亿美元，与生物技术公司Clavis Bio达成的战略合作，可获得至多72.5亿美元付款。 在文旅消费赛道，复星多个产品线取得新年开门红，有望拉动今年板块业绩的增长。其中，上海豫园商 城新春假期累计接待客流近120万人次，同比提升超20%；Club Med国内五家精致"一价全包"度假村春 节核心假期六日平均入住率达90%；三亚·亚特兰蒂斯春节假期九日总营业额突破1.24亿元，同比增长 20%，创下历史最佳表现。 此外，在保险赛道，复星国内 ...

2026年开年以来，随着创新成果的商业化落地及全球化运营的深入，复星国际核心主业延续了此前 强劲的增长势头，在文旅、消费、创新药等赛道迎来新突破。 文旅消费作为复星的核心主业之一，马年春节期间多条产品线展现了出强劲的增长势头。其中，上 海豫园商城新春假期累计接待客流近120万人次，同比提升超20%；Club Med国内五家精致"一价全 包"度假村春节核心假期六日平均入住率达90%；三亚·亚特兰蒂斯春节假期九日总营业额突破1.24亿 元，同比增长20%，创下历史最佳春节表现。 与此同时，春节期间，复星的创新药赛道也好消息不断。旗下的生物医药研发平台复宏汉霖宣布其 研发的HLX15-SC（重组抗CD38全人单克隆抗体注射液-皮下注射）1期临床试验申请分别获中国国家药 监局批准和美国食品药品管理局（FDA）批准。据了解，HLX15是达雷妥尤单抗生物类似药，目标市 场潜力较大，2024年全球销售额约128.8亿美元。而在2月22日，中国首个自主研发的利妥昔单抗生物类 似药——汉利康迎来上市七周年，该药曾一举填补了国产CD20单抗的空白，作为复星医药"十年磨一 剑"的成果，其标志着中国生物药研发迈出了从跟随到并跑的关键 ...

Core Insights - Fosun International has continued its strong growth momentum in 2026, particularly in sectors such as cultural tourism, consumer goods, and innovative pharmaceuticals, driven by the commercialization of innovative results and deepening global operations [1][2] Group 1: Cultural Tourism and Consumer Growth - During the Spring Festival, Fosun's cultural tourism segment showed robust growth, with Shanghai Yuyuan Mall receiving nearly 1.2 million visitors, a year-on-year increase of over 20% [1] - Club Med's five domestic resorts achieved an average occupancy rate of 90% during the Spring Festival core holiday period [1] - Atlantis Sanya reported a total revenue of 124 million yuan during the Spring Festival holiday, marking a 20% year-on-year growth and setting a record for the best performance during the Spring Festival [1] Group 2: Innovative Pharmaceuticals - Fosun's innovative pharmaceutical sector has seen significant advancements, with its subsidiary, Fuhong Hanlin, receiving clinical trial approvals for HLX15-SC from both the Chinese National Medical Products Administration and the FDA [2] - HLX15, a biosimilar to Daratumumab, has a projected global sales potential of approximately 12.88 billion yuan in 2024 [2] - In 2025, Fosun Pharma's innovative drug revenue exceeded 6.7 billion yuan, reflecting an 18.09% year-on-year increase, with innovative drugs accounting for 32% of the pharmaceutical segment [3] Group 3: Strategic Collaborations and Future Growth - Fosun Pharma's subsidiary, Yaoyou Pharmaceutical, signed a global exclusive licensing agreement with Pfizer for the oral GLP-1 drug YP05002, with potential total payments exceeding 2 billion dollars [4] - A strategic partnership with Clavis Bio aims to develop innovative therapies based on cutting-edge targets, with potential payments up to 7.25 billion dollars [4] - The innovative drug growth is further supported by the successful global development of core products from Fuhong Hanlin, which saw a stock price increase of approximately 150% in 2025 [4] Group 4: Globalization and Financial Performance - Fosun's overseas business revenue reached a historic high of 53% in the first half of 2025, reflecting its deep industry layout and operations in over 40 countries [6] - The overseas revenue from Fosun Pharma's innovative drugs grew by 184%, surpassing 10 billion yuan [7] - The financial health of Fosun is reinforced by strategic asset divestitures and a reduction in debt costs, with total debt to total capital ratio at 53% as of mid-2025 [8][9]

文旅消费作为复星的核心主业之一，马年春节期间多条产品线展现了出强劲的增长势头。其中，上海豫 园商城新春假期累计接待客流近120万人次，同比提升超20%；Club Med国内五家精致"一价全包"度假 村春节核心假期六日平均入住率达90%；三亚·亚特兰蒂斯春节假期九日总营业额突破1.24亿元，同比增 长20%，创下历史最佳春节表现。 与此同时，春节期间，复星的创新药赛道也好消息不断。旗下的生物医药研发平台复宏汉霖宣布其研发 的HLX15-SC（重组抗CD38全人单克隆抗体注射液-皮下注射）1期临床试验申请分别获中国国家药监局 批准和美国食品药品管理局（FDA）批准。据了解，HLX15是达雷妥尤单抗生物类似药，目标市场潜 力较大，2024年全球销售额约128.8亿美元。而在2月22日，中国首个自主研发的利妥昔单抗生物类似药 ——汉利康迎来上市七周年，该药曾一举填补了国产CD20单抗的空白，作为复星医药"十年磨一剑"的 成果，其标志着中国生物药研发迈出了从跟随到并跑的关键一步。 创新药等进入密集收获期，创新引擎动力强劲 2025年，复星的创新研发以肉眼可见的速度推进，尤其以创新药为代表，已取得了全球范围内的商业落 地 ...

Core Insights - Fosun has reported significant growth in its core sectors, including tourism, pharmaceuticals, and insurance, with notable achievements in early 2026 [1][2][3] Tourism Sector Performance - Fosun's Club Med resorts in China saw a threefold increase in inbound revenue compared to the same period last year, with a 33% revenue growth during the New Year period [1][2] - The company launched three major product lines in 2025, resulting in 14 project signings, including five super resorts and eight super tourism zones [2] - The average occupancy rate for three ice and snow resorts exceeded 97%, while two sunshine resorts doubled their revenue [2] Pharmaceutical Sector Developments - Fosun Pharma's subsidiary signed a global exclusive licensing agreement with Pfizer for a GLP-1 drug, with potential total payments exceeding $2 billion [3] - The company is also collaborating with Clavis Bio for innovative therapies, with potential payments up to $7.25 billion [3] - Fosun's innovative drugs are expected to achieve significant market breakthroughs in 2026, with several products anticipated to receive regulatory approvals [3] Insurance Sector Growth - Fosun's insurance companies reported substantial growth, with Fosun United Health Insurance's revenue reaching 7.84 billion yuan, a 50% increase year-on-year [3][4] - Fosun Baodexin Life Insurance achieved a 36.2% revenue growth, totaling 12.6 billion yuan, with a net profit increase of over 450% [3][4] Financial Health and Strategy - Fosun has maintained a strong financial position, with a debt-to-capital ratio of 53% and a decrease in debt costs [5][6] - The company successfully executed significant equity sales, raising substantial funds to support its core business focus [6] - Fosun plans to reduce interest-bearing debt by approximately 10 billion yuan annually over the next two to three years, aiming for an "investment-grade" rating [6] Future Prospects - Fosun is preparing for potential IPOs of two subsidiaries, which could enhance strategic synergies and investment returns [7] - The company is well-positioned to capitalize on opportunities in the aging population and the growing demand for health and wellness, as well as tourism in emerging markets [7][8]

Core Insights - The forum emphasized the resilience, innovation, and aspirations of Zhejiang merchants amidst the waves of the Chinese economy, with notable discussions on macroeconomic trends and opportunities for private enterprises [1] - Guo Guangchang expressed optimism for 2026, highlighting the gradual digestion of negative factors and the inherent resilience of the Chinese economy [1] Economic Resilience and Innovation - Guo noted that the current economic climate is warmer compared to the previous year, indicating a recovery in both weather and economic conditions [1] - He emphasized the importance of private enterprises, particularly in technology, showcasing their global competitiveness in emerging industries like AI, robotics, and biomedicine [3] - The success of Fosun's biopharmaceutical platform, including the global breakthroughs of its products, illustrates the potential for significant market opportunities, with several products having a global market potential of billions [3] Globalization and Market Strategy - Guo highlighted the competitive landscape between the US and China, asserting that the two economies are interconnected, which provides opportunities for collaboration despite competition [3] - Fosun's global strategy includes significant partnerships, such as the agreement with Pfizer for a GLP-1 drug, with a potential total value exceeding $2 billion, and a collaboration with Clavis Bio worth up to $7.25 billion [4] - The company aims to leverage China's market size and efficiency advantages to enhance its global presence, with overseas revenue reaching 46.67 billion yuan in the first half of 2025, accounting for 53% of total revenue [9] Consumer Market and Product Development - The focus on product strength and innovation is crucial for capturing opportunities in China's vast consumer market, which remains robust despite economic challenges [7] - Fosun's ventures in tourism and consumer goods have shown positive market responses, with high occupancy rates in hotels and successful product launches in the consumer sector [7][8] - New products from Fosun's ecosystem, such as the "Old Beijing Fresh Milk" and "Shede Zizai" liquor, have gained popularity, demonstrating the effectiveness of product innovation [8]

Core Viewpoint - The forum emphasizes the resilience, innovation, and aspirations of Zhejiang merchants amidst the waves of the Chinese economy, highlighting the importance of maintaining a competitive edge through innovation and market economy principles [3][13]. Economic Outlook - The current economic climate is warmer compared to the previous year, with negative factors gradually being digested, indicating the resilience of the Chinese economy [3][4]. - There is optimism for 2026, with expectations for significant growth and opportunities for businesses to excel [3][4]. Innovation and Competitiveness - The strength of China's economy is attributed to its market economy and the resilience of private enterprises, particularly in emerging sectors like AI, robotics, and biomedicine [4][14]. - Fosun's biopharmaceutical platform, Fuhong Hanlin, is set to achieve breakthroughs with multiple products expected to reach global markets by 2025, showcasing strong global competitiveness [4][14]. Globalization Strategy - Fosun is committed to globalization, with operations in over 40 countries and regions, and overseas revenue reaching 46.67 billion yuan, accounting for 53% of total revenue in the first half of 2025 [18]. - The company aims to leverage China's capabilities and resources to enhance its global presence and competitiveness [18]. Consumer Market Insights - The Chinese consumer market, with over a billion people, presents continuous opportunities, emphasizing the need for companies to enhance product quality and innovation [16][17]. - Fosun's ventures in tourism and consumer products have received positive market feedback, with high occupancy rates and successful product launches [16][17].

Core Viewpoint - The forum emphasizes the resilience, innovation, and aspirations of Zhejiang merchants amidst the waves of the Chinese economy, highlighting the importance of maintaining a competitive edge through innovation and market economy principles [3][13]. Economic Outlook - The current economic climate is warmer compared to the previous year, with negative factors gradually being digested, indicating the resilience of the Chinese economy [3][4]. - There is optimism for 2026, with expectations for significant growth and opportunities for businesses to excel [3][4]. Innovation and Competitiveness - The strength of China's economy is attributed to its market economy and the resilience of private enterprises, particularly in emerging sectors like AI, robotics, and biomedicine [4][14]. - Fosun's biopharmaceutical platform, Fuhong Hanlin, is set to achieve breakthroughs with multiple products expected to be globally competitive by 2025, including the world's first successful PD-1 monoclonal antibody for gastric cancer [4][14]. Globalization Strategy - Fosun is committed to globalization, with operations in over 40 countries and regions, and overseas revenue reaching 46.67 billion yuan, accounting for 53% of total revenue in the first half of 2025 [18]. - The company aims to leverage China's capabilities and resources to enhance its global presence and competitiveness [18]. Consumer Market Insights - The Chinese consumer market, with over a billion people, presents continuous opportunities, emphasizing the need for companies to enhance product quality and innovation [16][17]. - Fosun's ventures in tourism and consumer goods have seen positive market responses, with high occupancy rates in hotels and successful product launches [16][17].